Literature DB >> 29128052

The Intestinal Microbiome in Nonalcoholic Fatty Liver Disease.

Puneet Puri1, Arun J Sanyal2.   

Abstract

Nonalcoholic fatty liver disease is the most common cause of chronic liver disease in North America and is growing as a cause of chronic liver disease in many other parts of the world as well. It has 2 principal clinical-pathologic phenotypes: (1) nonalcoholic fatty liver and (2) nonalcoholic steatohepatitis. The development of both phenotypes is tightly linked to excess body weight and insulin resistance. This review discusses the emerging tools for the analysis of the microbiome, their limitations, and the existing literature with respect to the intestinal microbiome and their role in nonalcoholic fatty liver.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  16S pyrosequencing; Cirrhosis; Innate immune system; Intestinal permeability; Microbiome; Microbiota; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis

Mesh:

Substances:

Year:  2018        PMID: 29128052     DOI: 10.1016/j.cld.2017.08.009

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  13 in total

Review 1.  Microbiome diurnal rhythmicity and its impact on host physiology and disease risk.

Authors:  Samuel Philip Nobs; Timur Tuganbaev; Eran Elinav
Journal:  EMBO Rep       Date:  2019-03-15       Impact factor: 8.807

2.  The Intestinal Microbiome, Plasma Metabolome, and Liver Transcriptome: A Conspiracy Driving Hepatic Steatosis.

Authors:  Wajahat Z Mehal; Rohit Loomba
Journal:  Hepatology       Date:  2019-04-11       Impact factor: 17.425

3.  Gut microbiome features associated with liver fibrosis in Hispanics, a population at high risk for fatty liver disease.

Authors:  Suet-Ying Kwan; Jingjing Jiao; Aron Joon; Peng Wei; Lauren E Petty; Jennifer E Below; Carrie R Daniel; Xiaogang Wu; Jianhua Zhang; Robert R Jenq; P Andrew Futreal; Ernest T Hawk; Joseph B McCormick; Susan P Fisher-Hoch; Laura Beretta
Journal:  Hepatology       Date:  2021-12-13       Impact factor: 17.298

Review 4.  The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies.

Authors:  Marica Meroni; Miriam Longo; Paola Dongiovanni
Journal:  Nutrients       Date:  2019-11-04       Impact factor: 5.717

Review 5.  Toll-Like Receptors Recognize Intestinal Microbes in Liver Cirrhosis.

Authors:  Yujing Fan; Yunpeng Li; Yanjie Chu; Jing Liu; Lin Cui; Dekai Zhang
Journal:  Front Immunol       Date:  2021-02-23       Impact factor: 7.561

Review 6.  Novel therapeutic targets for cholestatic and fatty liver disease.

Authors:  Michael Trauner; Claudia Daniela Fuchs
Journal:  Gut       Date:  2021-10-06       Impact factor: 23.059

Review 7.  Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies?

Authors:  Agostino Di Ciaula; Salvatore Passarella; Harshitha Shanmugam; Marica Noviello; Leonilde Bonfrate; David Q-H Wang; Piero Portincasa
Journal:  Int J Mol Sci       Date:  2021-05-20       Impact factor: 5.923

Review 8.  Protocols for Mitochondria as the Target of Pharmacological Therapy in the Context of Nonalcoholic Fatty Liver Disease (NAFLD).

Authors:  Ignazio Grattagliano; Agostino Di Ciaula; Jacek Baj; Emilio Molina-Molina; Harshitha Shanmugam; Gabriella Garruti; David Q-H Wang; Piero Portincasa
Journal:  Methods Mol Biol       Date:  2021

Review 9.  Gut Microbiota's Relationship with Liver Disease and Role in Hepatoprotection by Dietary Natural Products and Probiotics.

Authors:  Xiao Meng; Sha Li; Ya Li; Ren-You Gan; Hua-Bin Li
Journal:  Nutrients       Date:  2018-10-08       Impact factor: 5.717

10.  Post-hoc analysis of a randomized controlled trial on the impact of pre-transplant use of probiotics on outcomes after liver transplantation.

Authors:  M Grąt; K Grąt; M Krawczyk; Z Lewandowski; M Krasnodębski; Ł Masior; W Patkowski; K Zieniewicz
Journal:  Sci Rep       Date:  2020-11-17       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.